Hello manoj kumar valluru,
Last week a paper was published describing that treated with the proteosome inhibitor Velcade could actually sensitize quiescent CML progenitors to killing by natural killer cells. This is important since CML is one of the situations where immunological control of cancer has been well documented.
Two patents in the area of stem cells were issued last week. # 7,435,718 discloses compositions of matter for antagonizing CXCR4 and # 7,435,592 covers T cells activated with anti-CD3 and anti-CD28 ! No joke ! this patent could be very useful given that anti-CD3 and anti-CD28 are the main ways of activating human T cells.
|
|
RMSC 2008 World Congress (2-4 December 2008)
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)
|
|
Thanks again for your help in supporting StemCellPatents.com.
We welcome your comments and suggestions! Tell us here.
Media Partnerships (NEW)